5 recruiting, 4 completed, 4 unknown, 3 not yet recruiting. 8 Phase 2, 6 Not applicable, 4 Phase 1, 2 Phase 3.
Follow Re-Irradiation: new trials by email Literature Review of Re-Irradiation trials Research Report on Re-Irradiation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Reirradiation and Total Ablative Strategies for Recurrent Gynecologic Cancer Reirradiation, Total Ablative Strategy - Recurrent Gynecologic Cancer, Recurrent Uterine Cancer | Recruiting | Affidea Nu-med Center of Oncological DIagnostics and Therapy | 500 | 2026-06-11 | 2026-10-16 | |
| aPBI Re-irradiation Reirradiation - Breast Cancer Recurrent | Phase 1 / Phase 2 | Not yet recruiting | Dartmouth-Hitchcock Medical Center | 30 | 2026-06-03 | 2026-05-28 |
| Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) Reirradiation - Radiotherapy Side Effect | Not yet recruiting | University of Aarhus | 500 | 2026-04-01 | 2026-04-14 | |
| Ablative Stereotactic MR-Guided Adaptive Reirradiation Reirradiation - Abdominal Cancer, Pelvic Cancer | Not applicable | Active not recruiting | Baptist Health South Florida | 10 | 2024-06-05 | 2026-02-17 |
| Lomustine With and Without Reirradiation for First Progression of Glioblastoma: a Randomized Phase III Study Lomustine, Reirradiation - First Progression of Glioblastoma | Phase 3 | Recruiting | European Organisation for Research and Treatment of Cancer - EORTC | 411 | 2024-03-15 | 2026-06-08 |
| Reirradiation and Niraparib in Patients With Recurrent Glioblastoma Niraparib, Re-irradiation (re-RT) - Recurrent Glioblastoma | Phase 1 | Withdrawn | University College, London | 2023-10-13 | 2024-03-26 | |
| RE-irradiation of Diffuse MIdline Glioma paTients Re-irradiation - Diffuse Midline Glioma, H3 K27M-Mutant, Diffuse Intrinsic Pontine Glioma | Not applicable | Not yet recruiting | Copenhagen University Hospital, Rigshospitalet | 59 | 2023-10-01 | 2023-10-23 |
| Radiotherapy & Total Neoadjuvant Therapy for Recurrent Rectal Cancer in Previously Irradiated Patients, an Italian Association for Radiotherapy and Clinical Oncology (AIRO)-GI Platform: a Multi-centre Prospective Observational Study Reirradiation - Rectal Neoplasm | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 88 | 2023-06-21 | 2023-08-09 | |
| The RECSUR-study: Resection Versus Best Oncological Treatment for Recurrent Glioblastoma (ENCRAM 2302) Re-resection, Temozolomide, Lomustine - Glioblastoma, Glioblastoma Multiforme | Recruiting | Jasper Gerritsen | 464 | 2023-01-01 | 2024-02-28 | |
| High Dose Re-Irradiation Utilizing Advanced Deformable Image Registration (DIR) and Individualized Organ At Risk (OAR) Dose Calculations With Organ Specific Toxicity Analysis Re-irradiation - Solid Tumor | Not applicable | Recruiting | Medical College of Wisconsin | 120 | 2022-06-13 | 2026-06-30 |
| DAHANCA 37. Re-irradiation With Proton Radiotherapy Re-irradiation - Head and Neck Neoplasms | Not applicable | Unknown | Danish Head and Neck Cancer Group | 20 | 2019-09-01 | 2020-09-25 |
| IMRT Combined With Toripalimab in Unresectable Locally Recurrent Nasopharyngeal Carcinoma. Tolipalimab, Reirradiation - Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms | Phase 2 | Unknown | Sun Yat-sen University | 25 | 2019-05-01 | 2022-04-29 |
| Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Re-irradiation (RT), Bevacizumab, Nivolumab - Glioblastoma | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 39 | 2018-11-12 | 2026-01-07 |
| Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma Pembrolizumab, Bevacizumab, Re-irradiation - Glioblastoma | Phase 2 | Completed | Dana-Farber Cancer Institute | 60 | 2018-09-28 | 2024-09-19 |
| REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma cemiplimab (monotherapy), cemiplimab (maintenance), Conventional or hypofractionated - Relapsed Solid Tumor, Refractory Solid Tumor | Phase 1 / Phase 2 | Terminated | Regeneron Pharmaceuticals | 57 | 2018-09-24 | 2025-04-08 |
| Re-Irradiation of Progressive or Recurrent DIPG re-irradiation - Recurrent or Progressive Diffuse Intrinsic Pontine Glioma | Not applicable | Completed | University of Calgary | 27 | 2017-04-15 | 2024-12-05 |
| Re-irradiation With Stereotactic Body Radiotherapy for Relapsed Pancreatic Cancer Re-irradiation with SBRT - Pancreatic Cancer | Not applicable | Unknown | Changhai Hospital | 30 | 2016-05-01 | 2023-05-25 |
| Reirradiation With Pembrolizumab in Locoregional Inoperable Recurrence or Second Primary Squamous Cell CA of the Head and Neck Reirradiation, MK-3475 - Recurrent Head and Neck Cancer, Carcinoma, Squamous Cell of Head and Neck | Phase 2 | Completed | Dan Zandberg | 48 | 2016-03-09 | 2025-03-06 |
| A Phase II Study of Pulse Reduced Dose Rate Radiation Therapy With Bevacizumab Bevacizumab, PRDR - Glioma | Phase 2 | Terminated | University of Wisconsin, Madison | 49 | 2012-12-03 | 2026-03-25 |
| Diffuse Intrinsic Pontine Glioma (DIPG) Reirradiation (ReRT) Radiation Therapy - Brain Cancer | Phase 1 / Phase 2 | Completed | M.D. Anderson Cancer Center | 12 | 2011-12-07 | 2022-10-20 |
Showing 20 of 21. Sign in to see all of them.
Glioblastoma (6) · Recurrence (4) · Diffuse Intrinsic Pontine Glioma (3) · Head and Neck Neoplasms (3) · Brain Neoplasms (2) · Glioma (2) · Astrocytoma (1) · Brain Stem Neoplasms (1) · Carcinoma, Squamous Cell (1) · Central Nervous System Neoplasms (1) · Fallopian Tube Neoplasms (1) · Fistula (1) · Nasopharyngeal Carcinoma (1) · Nasopharyngeal Diseases (1) · Nasopharyngeal Neoplasms (1)
Affidea Nu-med Center of Oncological DIagnostics and Therapy (1) · Baptist Health South Florida (1) · Changhai Hospital (1) · Copenhagen University Hospital, Rigshospitalet (1) · Dan Zandberg (1) · Dana-Farber Cancer Institute (1) · Danish Head and Neck Cancer Group (1) · Dartmouth-Hitchcock Medical Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · Fondazione Policlinico Universitario Agostino Gemelli IRCCS (1) · Gustave Roussy, Cancer Campus, Grand Paris (1) · Jasper Gerritsen (1) · M.D. Anderson Cancer Center (1) · Medical College of Wisconsin (1) · Memorial Sloan Kettering Cancer Center (1)
United States (10) · Belgium (2) · China (2) · Denmark (2) · France (2) · Germany (2) · Italy (2) · Netherlands (2) · Switzerland (2) · Australia (1) · Austria (1) · Canada (1) · Czechia (1) · New Zealand (1) · Norway (1)
Christian Grommes, MD (1) · Dan Zandberg, MD (1) · David A Reardon, MD (1) · Dusan Milanovic (1) · Elizabeth Gore, MD (1) · Giuseppe Minniti, Dr. (1) · H. Ian Robins, MD, Ph.D (1) · Huo Jun Zhang, MD., PH.D (1) · Jasper Gerritsen, MD PhD (1) · Kenneth Jensen (1) · Lucie Lafay-Cousin, MD (1) · Maja V Maraldo (1) · Matthias Preusser, Prof. (1)
PMID 34782428, PMID 38849943, PMID 39626445, PMID 39695675
R01CA187202 (1)